340 related articles for article (PubMed ID: 21470991)
1. Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study.
Hermsen IG; Fassnacht M; Terzolo M; Houterman S; den Hartigh J; Leboulleux S; Daffara F; Berruti A; Chadarevian R; Schlumberger M; Allolio B; Haak HR; Baudin E
J Clin Endocrinol Metab; 2011 Jun; 96(6):1844-51. PubMed ID: 21470991
[TBL] [Abstract][Full Text] [Related]
2. The lack of antitumor effects of o,p'DDA excludes its role as an active metabolite of mitotane for adrenocortical carcinoma treatment.
Hescot S; Paci A; Seck A; Slama A; Viengchareun S; Trabado S; Brailly-Tabard S; Al Ghuzlan A; Young J; Baudin E; Lombès M
Horm Cancer; 2014 Oct; 5(5):312-23. PubMed ID: 25026941
[TBL] [Abstract][Full Text] [Related]
3. RRM1 modulates mitotane activity in adrenal cancer cells interfering with its metabolization.
Germano A; Rapa I; Volante M; De Francia S; Migliore C; Berruti A; Papotti M; Terzolo M
Mol Cell Endocrinol; 2015 Feb; 401():105-10. PubMed ID: 25497672
[TBL] [Abstract][Full Text] [Related]
4. Rapidly progressing high o,p'DDD doses shorten the time required to reach the therapeutic threshold with an acceptable tolerance: preliminary results.
Faggiano A; Leboulleux S; Young J; Schlumberger M; Baudin E
Clin Endocrinol (Oxf); 2006 Jan; 64(1):110-3. PubMed ID: 16402938
[TBL] [Abstract][Full Text] [Related]
5. Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p'DDD) levels on the treatment of patients with adrenocortical carcinoma.
Baudin E; Pellegriti G; Bonnay M; Penfornis A; Laplanche A; Vassal G; Schlumberger M
Cancer; 2001 Sep; 92(6):1385-92. PubMed ID: 11745214
[TBL] [Abstract][Full Text] [Related]
6. [Practical use of o,p'DDD in adrenocortical carcinoma].
Bacchetta J; Droz JP
Bull Cancer; 2005 Mar; 92(3):273-9. PubMed ID: 15820922
[TBL] [Abstract][Full Text] [Related]
7. Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection.
Terzolo M; Baudin AE; Ardito A; Kroiss M; Leboulleux S; Daffara F; Perotti P; Feelders RA; deVries JH; Zaggia B; De Francia S; Volante M; Haak HR; Allolio B; Al Ghuzlan A; Fassnacht M; Berruti A
Eur J Endocrinol; 2013 Sep; 169(3):263-70. PubMed ID: 23704714
[TBL] [Abstract][Full Text] [Related]
8. Management of Cushing's syndrome due to ectopic adrenocorticotropin secretion with 1,ortho-1, para'-dichloro-diphenyl-dichloro-ethane: findings in 23 patients from a single center.
Donadille B; Groussin L; Waintrop C; Abbas H; Tenenbaum F; Dugué MA; Coste J; Bertagna X; Bertherat J
J Clin Endocrinol Metab; 2010 Feb; 95(2):537-44. PubMed ID: 20061433
[TBL] [Abstract][Full Text] [Related]
9. Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma.
Kerkhofs TM; Baudin E; Terzolo M; Allolio B; Chadarevian R; Mueller HH; Skogseid B; Leboulleux S; Mantero F; Haak HR; Fassnacht M
J Clin Endocrinol Metab; 2013 Dec; 98(12):4759-67. PubMed ID: 24057287
[TBL] [Abstract][Full Text] [Related]
10. Possible mechanism and treatment of o,p'DDD-induced hypercholesterolaemia.
Maher VM; Trainer PJ; Scoppola A; Anderson JV; Thompson GR; Besser GM
Q J Med; 1992 Sep; 84(305):671-9. PubMed ID: 1480741
[TBL] [Abstract][Full Text] [Related]
11. Lipoprotein-Free Mitotane Exerts High Cytotoxic Activity in Adrenocortical Carcinoma.
Hescot S; Seck A; Guerin M; Cockenpot F; Huby T; Broutin S; Young J; Paci A; Baudin E; Lombès M
J Clin Endocrinol Metab; 2015 Aug; 100(8):2890-8. PubMed ID: 26120791
[TBL] [Abstract][Full Text] [Related]
12. Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma.
Kroiss M; Plonné D; Kendl S; Schirmer D; Ronchi CL; Schirbel A; Zink M; Lapa C; Klinker H; Fassnacht M; Heinz W; Sbiera S
Eur J Endocrinol; 2016 Mar; 174(3):343-53. PubMed ID: 26671975
[TBL] [Abstract][Full Text] [Related]
13. Assessment of serum-free cortisol levels in patients with adrenocortical carcinoma treated with mitotane: a pilot study.
Alexandraki KI; Kaltsas GA; le Roux CW; Fassnacht M; Ajodha S; Christ-Crain M; Akker SA; Drake WM; Edwards R; Allolio B; Grossman AB
Clin Endocrinol (Oxf); 2010 Mar; 72(3):305-11. PubMed ID: 19473175
[TBL] [Abstract][Full Text] [Related]
14. High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up.
Mauclère-Denost S; Leboulleux S; Borget I; Paci A; Young J; Al Ghuzlan A; Deandreis D; Drouard L; Tabarin A; Chanson P; Schlumberger M; Baudin E
Eur J Endocrinol; 2012 Feb; 166(2):261-8. PubMed ID: 22048971
[TBL] [Abstract][Full Text] [Related]
15. Effects of mitotane on the hypothalamic-pituitary-adrenal axis in patients with adrenocortical carcinoma.
Reimondo G; Puglisi S; Zaggia B; Basile V; Saba L; Perotti P; De Francia S; Volante M; Zatelli MC; Cannavò S; Terzolo M
Eur J Endocrinol; 2017 Oct; 177(4):361-367. PubMed ID: 28780517
[TBL] [Abstract][Full Text] [Related]
16. Effect of o,p'DDD therapy on endogenous ACTH concentrations in dogs with hypophysis-dependent hyperadrenocorticism.
Nelson RW; Feldman EC; Shinsako J
Am J Vet Res; 1985 Jul; 46(7):1534-7. PubMed ID: 2992329
[TBL] [Abstract][Full Text] [Related]
17. Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma.
Megerle F; Herrmann W; Schloetelburg W; Ronchi CL; Pulzer A; Quinkler M; Beuschlein F; Hahner S; Kroiss M; Fassnacht M;
J Clin Endocrinol Metab; 2018 Apr; 103(4):1686-1695. PubMed ID: 29452402
[TBL] [Abstract][Full Text] [Related]
18. A high-pressure liquid chromatographic method for measuring mitotane [1,1-(o,p'-Dichlorodiphenyl)-2,2-dichloroethane] and its metabolite 1,1-(o,p'-Dichlorodiphenyl)-2,2-dichloroethene in plasma.
Andersen A; Warren DJ; Nome O; Vesterhus L; Slørdal L
Ther Drug Monit; 1995 Oct; 17(5):526-31. PubMed ID: 8585118
[TBL] [Abstract][Full Text] [Related]
19. Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma.
Malandrino P; Al Ghuzlan A; Castaing M; Young J; Caillou B; Travagli JP; Elias D; de Baere T; Dromain C; Paci A; Chanson P; Schlumberger M; Leboulleux S; Baudin E
Endocr Relat Cancer; 2010 Sep; 17(3):797-807. PubMed ID: 20592067
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study.
Bukowski RM; Wolfe M; Levine HS; Crawford DE; Stephens RL; Gaynor E; Harker WG
J Clin Oncol; 1993 Jan; 11(1):161-5. PubMed ID: 8418229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]